Merck KGaA pays 130% premium for Silence RNAi asset
Merck KGaA is spending $1.3 billion to buy Silence Therapeutics, a 130% premium that marks the second-highest markup on a major biotech deal this year
Takeda
Every Fin-node story mentioning Takeda — 2 stories, newest first.
Takeda · 2 stories
Iambic prices $150 million IPO at $16 a share
Iambic Therapeutics raised $150 million in an initial public offering on Wednesday, selling about 9.4 million shares at $16 each to begin trading on t